Humacyte Inc.

1.46
-0.25 (-14.37%)
At close: Apr 01, 2025, 3:59 PM

Humacyte Statistics

Share Statistics

Humacyte has 153.67M shares outstanding. The number of shares has increased by 29.04% in one year.

Shares Outstanding 153.67M
Shares Change (YoY) 29.04%
Shares Change (QoQ) 19.43%
Owned by Institutions (%) 35.25%
Shares Floating 124.68M
Failed to Deliver (FTD) Shares 283.3K
FTD / Avg. Volume 9.76%

Short Selling Information

The latest short interest is 25.64M, so 19.93% of the outstanding shares have been sold short.

Short Interest 25.64M
Short % of Shares Out 19.93%
Short % of Float 24.56%
Short Ratio (days to cover) 3.04

Valuation Ratios

The PE ratio is -2.65 and the forward PE ratio is -5.34. Humacyte's PEG ratio is 0.01.

PE Ratio -2.65
Forward PE -5.34
PS Ratio 0
Forward PS 0.3
PB Ratio 21.68
P/FCF Ratio -3.89
PEG Ratio 0.01
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Humacyte Inc..

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.52, with a Debt / Equity ratio of 4.25.

Current Ratio 4.52
Quick Ratio 4.52
Debt / Equity 4.25
Total Debt / Capitalization 80.94
Cash Flow / Debt -1.27
Interest Coverage -88.38

Financial Efficiency

Return on equity (ROE) is -8.18% and return on capital (ROIC) is -140.81%.

Return on Equity (ROE) -8.18%
Return on Assets (ROA) -0.86%
Return on Capital (ROIC) -140.81%
Revenue Per Employee $0
Profits Per Employee $-605,333.33
Employee Count 183
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -43.19% in the last 52 weeks. The beta is 1.36, so Humacyte's price volatility has been higher than the market average.

Beta 1.36
52-Week Price Change -43.19%
50-Day Moving Average 3.57
200-Day Moving Average 5.16
Relative Strength Index (RSI) 24.34
Average Volume (20 Days) 2.9M

Income Statement

Revenue n/a
Gross Profit -76.55M
Operating Income -100.05M
Net Income -110.78M
EBITDA -96.46M
EBIT n/a
Earnings Per Share (EPS) -1.07
Full Income Statement

Balance Sheet

The company has 80.45M in cash and 57.51M in debt, giving a net cash position of 22.94M.

Cash & Cash Equivalents 80.45M
Total Debt 57.51M
Net Cash 22.94M
Retained Earnings -537.31M
Total Assets 114.76M
Working Capital 2.06M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -73.31M and capital expenditures -2.28M, giving a free cash flow of -75.58M.

Operating Cash Flow -73.31M
Capital Expenditures -2.28M
Free Cash Flow -75.58M
FCF Per Share -0.73
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

HUMA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -62.57%
FCF Yield -28.85%
Dividend Details

Analyst Forecast

The average price target for HUMA is $14, which is 718.7% higher than the current price. The consensus rating is "Buy".

Price Target $14
Price Target Difference 718.7%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score -11.14
Piotroski F-Score 3